All In MedTech

Device Trial Radar · NCT03618095

REPRISE IV: LOTUS Edge Valve System in Intermediate Surgical Risk Subjects

REPRISE IV: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of LOTUS Edge Valve System in IntermediatE Surgical Risk Subjects

Last checked: Nov 20, 2026Latest source record: Dec 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

382

Actual

Start

Jan 14, 2019

Primary completion

Mar 30, 2021

Study completion Mar 31, 2021

Sponsor

Lead sponsor
Boston Scientific CorporationPublic (BSX)
Sponsor type
Industry
First posted
Aug 7, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

REPRISE IV: REpositionable Percutaneous Replacement of Stenotic Aortic Valve through Implantation of LOTUS Edge Valve System in IntermediatE Surgical Risk Subjects

Conditions

  • Aortic Valve Stenosis

Interventions

  • LOTUS Edge Valve SystemDevice

    TAVR with the LOTUS Edge Valve System

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of All-cause Mortality and All Stroke.Time frame: 1 year post index procedure and device implantation

Locations

50 sites in 2 countries. Site status is shown where the registry gives one.

  • Huntsville Hospital

    Huntsville, Alabama

  • Tucson Medical Center

    Tucson, Arizona

  • Arkansas Heart Hospital

    Little Rock, Arkansas

47 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.